A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects with Moderate to Severe Atopic Dermatitis

Trial Profile

A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects with Moderate to Severe Atopic Dermatitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 07 Sep 2017 Additional data will be presented at an upcoming medical meeting and published in a peer-reviewed publication, according to an AbbVie media release.
    • 07 Sep 2017 Top-line results published in an AbbVie media release.
    • 07 Sep 2017 Primary endpoint (Mean Percentage Change in EASI score) has been met, according to an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top